1
Clinical Trials associated with BT-1053BT-1053在复发/难治B细胞淋巴瘤患者中的耐受性与药代动力学I期临床研究
[Translation] Phase I clinical study of tolerability and pharmacokinetics of BT-1053 in patients with relapsed/refractory B-cell lymphoma
主要目的是评估BT-1053单药口服给药在复发/难治B细胞淋巴瘤患者中的安全性和耐受性,以确定最大耐受剂量(MTD)和推荐II期临床研究的使用剂量(RP2D)。次要目的是确定BT-1053在复发/难治B细胞淋巴瘤患者中的药代动力学参数,初步评估BT-1053在部分复发/难治B细胞性非霍奇金瘤亚型中的总体有效率。
[Translation] The primary objective is to evaluate the safety and tolerability of BT-1053 monotherapy in patients with relapsed/refractory B-cell lymphoma, in order to determine the maximum tolerated dose (MTD) and the recommended dose (RP2D) for Phase II clinical studies. The secondary objective is to determine the pharmacokinetic parameters of BT-1053 in patients with relapsed/refractory B-cell lymphoma and to preliminarily evaluate the overall efficacy of BT-1053 in some relapsed/refractory B-cell non-Hodgkin's tumor subtypes.
100 Clinical Results associated with BT-1053
100 Translational Medicine associated with BT-1053
100 Patents (Medical) associated with BT-1053
100 Deals associated with BT-1053